Core Viewpoint - Biohaven's shares experienced a significant decline of over 40% following the U.S. Food and Drug Administration's decision to not approve its experimental treatment for a rare brain disorder [1] Company Summary - Biohaven's stock price fell more than 40% on Wednesday [1] - The decline was triggered by the FDA's rejection of its experimental treatment [1] Industry Summary - The news highlights the challenges faced by companies in the pharmaceutical industry, particularly in the approval process for new treatments [1]